Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into an agreement allowing Eli Lilly and Company (NYSE: LLY) select access to research from its osteoarthritis genomic biomarker program

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ-; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Behavior changing strategies may improve medical adherence

Taking medication as the doctor prescribes is crucial to improving health. However, 26 to 59 percent of older adults do not adhere to instructions, according to a 2003 study published in Drugs and Aging. In a new study, researchers at the University of Missouri found that applying behavior changing strategies, such as using pill boxes or reducing the number of daily doses, can improve patients' abilities to take their medications as required.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

Dartmouth explores glucorticoid side effects on bladder-cancer patients

In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

27 Oct 2009

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

26 Oct 2009

Tart cherry juice may help runners recover quickly and effectively from post-race pain

From gold medalists to weekend warriors, athletes at every level are in search of new ways to reduce pain and enhance post-exercise recovery. Recent research shows that drinking tart cherry juice may help runners recover more quickly and effectively from post-race pain.

26 Oct 2009

CMSC analyses patient self-management in Multiple Sclerosis

The Consortium of Multiple Sclerosis Centers (CMSC) released a white paper, written by a panel chaired by CMSC member Robert T. Fraser, Ph.D., of the University of Washington Rehabilitation Research and Training Center in Seattle, Washington, analyzing patient self-management in Multiple Sclerosis (MS) to develop recommendations for best practices aimed at improving patients' lives.

26 Oct 2009

UAB to create national database and repository to identify medications for rheumatoid arthritis

The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA).

24 Oct 2009

LifeLock and Arthritis Foundation announce new partnership deal

With identity theft complaints reaching a 5-year high, and the cost to consumers increasing, the longer the fraud goes undetected, according to Javelin Strategy & Research, the urgency to guard against this crime has increased as well.

24 Oct 2009

Cohen Independent Research Group publishes a report profiling Nutra Pharma

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Cohen Independent Research Group has published a report profiling Nutra Pharma Corporation.

24 Oct 2009

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia.

23 Oct 2009

Workers with MetS can cost employers up to $5,867 in health care annually: Study

Someone healthy enough to work could still cost an employer more than $4,000 annually in unnecessary health care costs.

23 Oct 2009

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants.

23 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Eli Lilly receives access to GeneNews' osteoarthritis genomic biomarker program

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

LX211 may become the first approved oral treatment for modifying the course of uveitis

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Behavior changing strategies may improve medical adherence

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Dartmouth explores glucorticoid side effects on bladder-cancer patients

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

Tart cherry juice may help runners recover quickly and effectively from post-race pain

CMSC analyses patient self-management in Multiple Sclerosis

UAB to create national database and repository to identify medications for rheumatoid arthritis

LifeLock and Arthritis Foundation announce new partnership deal

Cohen Independent Research Group publishes a report profiling Nutra Pharma

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Workers with MetS can cost employers up to $5,867 in health care annually: Study

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in